GPA33 and neoplasm: The selective conveying of doxorubicin to colon cancer cells approached by encapsulating doxorubicin in tumor-derived exosomes from the human colorectal carcinoma LIM1215 cell line covered with antibodies directed against A-33, a cell surface glycoprotein overexpressed on colorectal cancer cells, produced promising results on tumor growth in nude mice [184].